TP53 and medulloblastoma: In a historic cohort of n = 37 patients with SHH-activated, germline TP53-mutated medulloblastoma treated with surgery, chemotherapy and radiotherapy, 3- and 5-year EFS were 20% and 16%, respectively, and no long-term survivors were detected (Milde, personal communication).